Sanquin Home Sanquin Home Sanquin
Home ● Contact ● Sanquin ● News ● Jobs ● Sitemap ●
Diagnostic Services
 		●
Products
 		●
Research
 		●
Education & Training
 		●
Business Activities
Yvette (Y) van Hensbergen PhD

Department: Clinical Transfusion Medicine

E-mail: y.vanhensbergen@sanquin.nl

Training:
Medical Biology, Free University, Amsterdam

Thesis:
The role of CD13/Aminipeptidase N in vascular and ovarian cancer biology
12 May 2004
Promotor: Prof. dr. H.M. Pinedo and prof. dr. V.W.M. van Hinsbergh
Faculty of Medical Oncology, Free University Medical Center, Amsterdam.

Research interests:
The research projects aim at the improving the outcome of stem cell transplantation with cord blood stem cells. This includes ex vivo expansion of the stem cells as well as co-transplantation with other cells. The current focus is on combining ex vivo expansion with multiple cord blood transplantation. In addition, we are working on the development of new products from cord blood.

Technology:
Isolation of specific cell populations; culturing of cells; hematopoietic colony forming assays; flowcytometry; immunocytochemistry; in vitro migration assays; in vivo analysis of stem cell engraftment.

Resume:
1993-1993Free University Amsterdam, Medical Biology
1997-1998 Johns Hopkins University, Department of Oncology, Baltimore, U.S.A., Research Traineeship
1998-2003Free University Medical Center, Department of Medical Oncology, PhD student
2003-2007Sanquin Blood Bank, Leiden, Scientist
2007-presentSanquin Blood Bank, Leiden, Senior Scientist
2008-2010Sanquin Blood Bank, Amsterdam & Ormit, de Bilt, Management Development Trainee

Sanquin Publications

Other publications
1. Hansma AH, van Hensbergen Y, Kuenen BC, van Diest PJ, Hanemaaijer R, Meijer S, Pinedo HM and Hoekman K. A patient with a VEGF and endostatin producing gastrointestinal autonomic nerve tumour. J Clin Pathol 2004; 57:536-8.
2. Van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MC, Hoekman K, Pinedo HM and Boven E. Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin.Cancer Res 2004; 10:1180-91.
3. Pinedo HM, Buter J, Luykx-de Bakker SA, Pohlmann PR, van Hensbergen Y, Heideman DA, van Diest PJ, de Gruijl TD and van der Wall E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF. effect on tumour-draining lymph node dendritic cells. Eur J Cancer; 2003l 39:1061-7.
4. van Hensbergen Y, Broxterman HJ, Peters E, Rana S, Elderkamp YW, van Hinsbergh VW and Koolwijk P. Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix. Thromb Haemost 2003; 90:921-9.
5. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM and Hoekman K. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 2002; 8:3747-54.
6. van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, Heijn M, Boven E, Hoekman K and Pinedo HM. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol 2002; 63: 897-908.
7. van Hensbergen Y, Luykx-de Bakker SA, Heideman DA, Meijer GA, Pinedo HM and van Diest PJ. Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: a methodological study. Anal Cell Pathol 2001; 22:143-9.
8. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, JansenG. and Peters GJ. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999; 5:643-54.
9. Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El Deiry WS, Fuchs EJ and Bedi A. p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 1998; 58: 4531-6.

Top



« back